<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">465773273</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323111935.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170327e19901001xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF00402624</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF00402624</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Transdermal delivery of 5-fluorouracil through skin of hairless mice and humans in vitro: a comparison of the effect of formulations and a prodrug</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[E. Sherertz, K. Sloan, R. McTiernan]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Summary: A 2% commercial solution formulation of 5-fluorouracil (5-FU) was significantly better at delivering 5-FU than either a 1% or 5% solution. Among single component suspension formulations the highest transdermal delivery was obtained from the vehicle in which 5-FU was least soluble, isopropyl myristate (IPM), while changes in the total suspended concentration of 5-FU in propyleneglycol (PG) had no significant effect on transdermal delivery by those suspensions. A prodrug of 5-FU/IPM was significantly better at delivering 5-FU than any of the formulations. The trends in relative rates of delivery of 5-FU by the formulations and the prodrug were the same in skin of hairless mice and humans. The mouse skin was about ten times more permeable than the human skin. Second application studies to assess skin damage caused by the formulations also showed the same trend in skin of hairless mice and humans: all of the formulations caused some damage.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Springer-Verlag, 1990</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Transdermal delivery</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Isopropyl myristate</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Skin</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Diffusion cell experiment</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">5-Fluorouracil (prodrug of 5-FU)</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Sherertz</subfield>
   <subfield code="D">E.</subfield>
   <subfield code="u">Department of Medicine, Veterans Administration Medical Center (Research Service) and University of Florida, Gainesville, Florida</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Sloan</subfield>
   <subfield code="D">K.</subfield>
   <subfield code="u">Department of Medicinal Chemistry, University of Florida, Gainesville, Florida</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">McTiernan</subfield>
   <subfield code="D">R.</subfield>
   <subfield code="u">Veterans Administration Medical Center, (Research Service), Gainesville, Florida, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Archives of Dermatological Research</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">282/7(1990-10-01), 463-468</subfield>
   <subfield code="x">0340-3696</subfield>
   <subfield code="q">282:7&lt;463</subfield>
   <subfield code="1">1990</subfield>
   <subfield code="2">282</subfield>
   <subfield code="o">403</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF00402624</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF00402624</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Sherertz</subfield>
   <subfield code="D">E.</subfield>
   <subfield code="u">Department of Medicine, Veterans Administration Medical Center (Research Service) and University of Florida, Gainesville, Florida</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Sloan</subfield>
   <subfield code="D">K.</subfield>
   <subfield code="u">Department of Medicinal Chemistry, University of Florida, Gainesville, Florida</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">McTiernan</subfield>
   <subfield code="D">R.</subfield>
   <subfield code="u">Veterans Administration Medical Center, (Research Service), Gainesville, Florida, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Archives of Dermatological Research</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">282/7(1990-10-01), 463-468</subfield>
   <subfield code="x">0340-3696</subfield>
   <subfield code="q">282:7&lt;463</subfield>
   <subfield code="1">1990</subfield>
   <subfield code="2">282</subfield>
   <subfield code="o">403</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
